Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02654340
Other study ID # TSC 08-2018
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date August 1, 2018
Est. completion date December 30, 2022

Study information

Verified date February 2023
Source CENTOGENE GmbH Rostock
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s


Description:

Tuberous Sclerosis Complex (TSC) is an autosomal dominant genetic disorder characterized by the growth of numerous tumors in different body parts related to dysregulation of the mechanistic target of rapamycin (mTOR) pathway. The overall incidence of TSC is estimated to be as high as 1 in 6000 to 10,000 live birth.The main aspects of TSC that influence the quality of life are associated with the brain: seizures, evelopmental delay, intellectual disability, and autism. However, the incidence and severity of the various aspects of TSC can vary widely. TSC is generally caused by pathogenic variants in the tumor suppressor genes: TSC1 and TSC2. Confirmation of a clinical diagnosis of tuberous sclerosis is performed via TSC1 and TSC2 sequencing. There is no cure for TSC, therefore symptomatic therapy is the best possible choice, including mTOR inhibitors, vigabatrin and other antiepileptic drugs for the seizures, and neurosurgery in cases of life-threatening neurological symptoms. The aim of the study is established TSC specific biomarker/s. Such biomarkers aim to facilitate the diagnosis, treatment personalization and monitoring.


Recruitment information / eligibility

Status Terminated
Enrollment 20
Est. completion date December 30, 2022
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 2 Years to 50 Years
Eligibility INCLUSION CRITERIA - Informed consent is obtained from the participant or from the parent / legal guardian - Participant is aged between 2 and 50 years - Diagnosis of TSC is genetically confirmed by CENTOGENE EXCLUSION CRITERIA - Inability to provide informed consent - Participant is younger than 2 or older than 50 years - Diagnosis of TSC is not genetically confirmed by CENTOGENE

Study Design


Locations

Country Name City State
Albania University Hospital Center Mother Teresa Tirana
Egypt Department of Pediatrics, Alexandria University Children's Hospital Alexandria
Georgia Departmnet of Molecular and Medical Genetics, Tbilisi State Medical University Tbilisi
India Department of Pediatric Genetics, Amrita Institute of Medical Sciences & Research Centre Cochin Kerala
Lithuania Rare diseases coordinating centre, Vilnius University Hospital Santaros klinikos Vilnius
Pakistan Departmnet of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health Lahore
Romania Emergency Hospital for Children "Louis Turcanu" Timisoara
Sri Lanka Lady Ridgeway Hospital for Children Colombo

Sponsors (1)

Lead Sponsor Collaborator
CENTOGENE GmbH Rostock

Countries where clinical trial is conducted

Albania,  Egypt,  Georgia,  India,  Lithuania,  Pakistan,  Romania,  Sri Lanka, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of TSC biomarker/s All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC. 36 months
Secondary Exploring the clinical robustness, specificity, and longterm variability of TSC biomarker/s Samples will be analyzed for the candidate biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC. 36 months
See also
  Status Clinical Trial Phase
Completed NCT01687179 - Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis Phase 1
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed NCT00552955 - Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Unknown status NCT00490789 - Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Phase 2
Not yet recruiting NCT05087134 - Characterizing LAM With 11C-Choline PET/CT Early Phase 1
Completed NCT02009241 - Pulmonary Rehabilitation in Lymphangioleiomyomatosis N/A
Recruiting NCT05190627 - Effect of Loratadine in Lymphangioleiomyomatosis Phase 2
Completed NCT05323370 - Lymphangioleiomyomatosis, a Study on Cathepsin K
Completed NCT02859194 - The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients N/A
Completed NCT01353209 - Letrozole for Lymphangioleiomyomatosis Phase 2
Completed NCT03253913 - Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial Phase 2
Recruiting NCT02432560 - Safety and Durability of Sirolimus for Treatment of LAM
Completed NCT02061397 - Safety of Simvastatin in LAM and TSC Phase 1/Phase 2
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Recruiting NCT04577937 - Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis N/A
Completed NCT00005906 - Treatment With Octreotide in Patients With Lymphangioleiomyomatosis Phase 2
Recruiting NCT01799538 - Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis Phase 1/Phase 2
Completed NCT00989742 - Doxycycline In Lymphangioleiomyomatosis (LAM) Phase 4
Recruiting NCT06160310 - Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
Enrolling by invitation NCT05727852 - Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases